Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation.
Joseph B LermanCynthia L GreenMaria R MolinaValmiki MaharajJuan M Ortega-LegaspiSounok SenMaureen FlatteryEileen K MaziarzKeyur B ShahCindy M MartinTamas AlexyPalak ShahAlanna A MorrisAdam D DeVoreRobert T ColePublished in: Clinical transplantation (2023)
The use of a PET CMV prophylaxis strategy in intermediate risk HT recipients associated with increased risk of CMV infection and CMV-related hospitalization, and may associate with worse post-HT graft outcomes.